Correlation Engine 2.0
Clear Search sequence regions


  • blood (1)
  • calcium (1)
  • humans (1)
  • ischemia (6)
  • limb (7)
  • patients (6)
  • phase (2)
  • pitavastatin (6)
  • quinolines (2)
  • Sizes of these terms reflect their relevance to your search.

    To assess the results of a phase I/IIa open-label dose-escalation clinical trial of 5-day repeated intramuscular administration of pitavastatin-incorporated poly (lactic-co-glycolic acid) nanoparticles (NK-104-NP) in patients with chronic limb threatening ischemia (CLTI). NK-104-NP was formulated using an emulsion solvent diffusion method. NK-104-NP at four doses (nanoparticles containing 0.5, 1, 2, and 4 mg of pitavastatin calcium, n=4 patients per dose) was investigated in a dose-escalation manner and administered intramuscularly into the ischemic limbs of 16 patients with CLTI. The safety and therapeutic efficacy of treatment were investigated over a 26-week follow-up period. No cardiovascular or other serious adverse events caused by NK-104-NP were detected during the follow-up period. Improvements in Fontaine and Rutherford classifications were noted in five patients (one, three, and one in the 1-, 2-, and 4-mg dose groups, respectively). Pharmacokinetic parameters including the maximum serum concentration and the area under the blood concentration-time curve increased with pitavastatin treatment in a dose-dependent manner. The area under the curve was slightly increased at day 5 compared with that at day 1 of treatment, although the difference was not statistically significant. This is the first clinical trial of pitavastatin-incorporated nanoparticles in patients with CLTI. Intramuscular administration of NK-104-NP to the ischemic limbs of patients with CLTI was safe and well tolerated and resulted in improvements in limb function.

    Citation

    Takuya Matsumoto, Shinichiro Yoshino, Tadashi Furuyama, Koichi Morisaki, Kaku Nakano, Jun-Ichiro Koga, Yoshihiko Maehara, Kimihiro Komori, Masaki Mori, Kensuke Egashira. Pitavastatin-Incorporated Nanoparticles for Chronic Limb Threatening Ischemia: A Phase I/IIa Clinical Trial. Journal of atherosclerosis and thrombosis. 2022 May 01;29(5):731-746

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33907060

    View Full Text